🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "major milestone" in the fight against superbug strains of the infection, according to researchers.

A Global Challenge

Cases of gonorrhoea are increasing globally, with figures suggesting more than 82 million instances per year. Notably increased rates are seen in Africa and countries within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Across England, cases have reached a all-time high, while rates across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely advancement in the face of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce available drugs presently on offer.”

Public health authorities are increasingly worried about the increase in drug-resistant strains. The World Health Organization has designated it as a "critical concern". Ongoing monitoring showed that resistance to primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Treatment Options Receive Authorization

Zoliflodacin, also known as a brand name, was authorized by the US FDA in mid-December for combating gonorrhoea. This STI can lead to major issues, including infertility. Scientists believe that focused deployment of this new drug will help slow the development of resistance.

Another new antibiotic, developed by the pharmaceutical company GSK, also received approval in concurrent days. This drug, which is employed against urinary tract infections, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment stemmed from a new, not-for-profit approach for medication research. The non-profit organisation GARDP partnered with the drug firm Innoviva to bring it to fruition.

“This milestone represents a huge turning point in the management of superbug gonorrhoea, which previously has been staying ahead of antibiotic development.”

Clinical Trial Data and Worldwide Availability

According to data released by a prominent scientific publication, zoliflodacin eradicated more than 90% of cases of the STI. This puts it on an comparable level with the typical regimen, which combines a dual-drug approach. The research involved hundreds of participants from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, the non-profit has the ability to register and commercialise the drug in many developing nations.

Medical professionals on the front lines have shared hope. Having a single-dose, oral treatment of this kind is described as a "game-changer" for gonorrhoea control. This is deemed crucial to reduce the burden of the illness for people and to stop the proliferation of extremely resistant gonorrhoea globally.